(5Z)-2H-1,5-Oxazocine | 292-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环化合物
• 英文名称: (5Z)-2H-1,5-Oxazocine
• 英文别名: 2H-1,5-oxazocine
• CAS: 292-93-3
• 化学式: C₆H₇NO
• 分子量: 109.13
• InChiKey: PEKMXQCZRIQIII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NOVEL SEQUENCES ENCODING HAPATITIS C VIRUS GLYCOPROTEINS
  申请人：PROGENICS PHARMACEUTICALS, INC.

  公开号：EP1687325A2

  公开（公告）日：2006-08-09
• EP1687325A4
  申请人：——

  公开号：EP1687325A4

  公开（公告）日：2008-11-12
• L-SIGN POLYMORPHISMS AND METHODS INVOLVING USE OF SAME
  申请人：PROGENICS PHARMACEUTICALS, INC.

  公开号：EP1733057A2

  公开（公告）日：2006-12-20
• [EN] NOVEL SEQUENCES ENCODING HAPATITIS C VIRUS GLYCOPROTEINS<br/>[FR] NOUVELLES SEQUENCES DE CODAGE DE GLYCOPROTEINES DU VIRUS DE L'HEPATITE C
  申请人：PROGENICS PHARM INC

  公开号：WO2005047481A2

  公开（公告）日：2005-05-26

  The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder.
• [EN] L-SIGN POLYMORPHISMS AND METHODS INVOLVING USE OF SAME<br/>[FR] POLYMORPHISMES DE L-SIGN ET PROCEDES METTANT EN OEUVRE L'UTILISATION DE CEUX-CI
  申请人：PROGENICS PHARM INC

  公开号：WO2005100601A2

  公开（公告）日：2005-10-27

  This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated with infection by pathogens, including hepatitis C virus, that bind to particular L-SIGN allelic variants. The invention further provides methods for predicting the resistance or susceptibility of a subject to pathogen infection.